- Trials with a EudraCT protocol (421)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
421 result(s) found for: Receptor Site.
Displaying page 1 of 22.
EudraCT Number: 2018-004557-24 | Sponsor Protocol Number: UKM17_0056 | Start Date*: 2019-07-29 | |||||||||||
Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel | |||||||||||||
Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002113-39 | Sponsor Protocol Number: BAY88-8223/16298 | Start Date*: 2014-10-29 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ... | |||||||||||||
Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005486-75 | Sponsor Protocol Number: I3Y-MC-JPBY | Start Date*: 2015-07-24 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Mo... | |||||||||||||
Medical condition: Postmenopausal Women with Hormone Receptor Postive, HER2 Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006889-29 | Sponsor Protocol Number: MEC-2008-322 | Start Date*: 2009-02-25 |
Sponsor Name:ErasmusMC | ||
Full Title: A pilotstudy comparing systemic versus locoregional injection of radiolabelled somatostatin analogues in patients with neuroendocrine Gastro-Entero_Pancreatic (GEP) tumors. | ||
Medical condition: Uptake of Octreoscan in sst-2 receptor positive Gastro Entero Pancreatic neuroendocrine tumors injected in systemical and locoregional way. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002114-23 | Sponsor Protocol Number: BAY88-8223/17096 | Start Date*: 2015-10-26 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe... | |||||||||||||
Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005954-22 | Sponsor Protocol Number: VEG108843 | Start Date*: 2008-06-03 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus p... | |||||||||||||
Medical condition: Advanced or metastatic hormone receptor positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004139-62 | Sponsor Protocol Number: CRAD001JES13 | Start Date*: 2014-01-02 | |||||||||||
Sponsor Name:Novartis Farmacéutica S. A. | |||||||||||||
Full Title: A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the f... | |||||||||||||
Medical condition: Estrogen receptor or progesterone receptor positive locally advanced or metastatic breast cancer in postmenopausal women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004867-38 | Sponsor Protocol Number: AUTO-LT1 | Start Date*: 2018-05-18 |
Sponsor Name:Autolus Limited | ||
Full Title: Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors. | ||
Medical condition: Potential malignancy in patients who received treatment with Autolus' CAR T cell therapy. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002005-36 | Sponsor Protocol Number: RM-493-015 | Start Date*: 2017-10-30 |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency... | ||
Medical condition: Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005835-87 | Sponsor Protocol Number: GBG41 | Start Date*: 2006-08-16 |
Sponsor Name:GermanBreastGroup | ||
Full Title: A randomized discontinuation phase II study to determine the efficacy of RAD001 in breast cancer patients with bone metastases | ||
Medical condition: Bone metasatsis, Breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004035-38 | Sponsor Protocol Number: GIM16-FEVEX | Start Date*: 2015-06-17 | |||||||||||
Sponsor Name:CONSORZIO ONCOTECH | |||||||||||||
Full Title: Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopaus... | |||||||||||||
Medical condition: Hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006796-80 | Sponsor Protocol Number: TES10897 | Start Date*: 2009-04-23 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: The QUTIE Study: A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc interval in Cancer Patients treated with Docetaxel | |||||||||||||
Medical condition: Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001455-39 | Sponsor Protocol Number: OPN-305-102 | Start Date*: 2012-10-10 | |||||||||||
Sponsor Name:Opsona Therapeutics Ltd | |||||||||||||
Full Title: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanis... | |||||||||||||
Medical condition: Prevention of Kidney Graft Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003530-16 | Sponsor Protocol Number: PM0259CA231B0 | Start Date*: 2012-11-14 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative p... | |||||||||||||
Medical condition: advanced breast cancer with estrogen receptor positive and HER2 negative. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000849-38 | Sponsor Protocol Number: CRAD001C2223 | Start Date*: 2005-08-03 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line t... | ||
Medical condition: The treatment of advanced breast cancer aims at reducing tumor size, slowing progression and metastasis and reducing complications such as fatigue, bone fracture and hypercalcemia. Women with tumor... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-000547-17 | Sponsor Protocol Number: FPA008-002 | Start Date*: 2015-11-18 | |||||||||||
Sponsor Name:Five Prime Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2 Study of FPA008, an anti-CSF1 Receptor Antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT) | |||||||||||||
Medical condition: Pigmented villonodular synovitis (PVNS)/Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001835-29 | Sponsor Protocol Number: 201900231 | Start Date*: 2021-01-28 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Canagliflozin REnal Distribution Intervention Trial (CREDIT); A feasibility study for the use of 18F-canagliflozin to quantify individual differences in target-site exposure in diabetes patients. | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001488-60 | Sponsor Protocol Number: WSG-AM11 | Start Date*: 2020-07-09 |
Sponsor Name:Westdeutsche Studiengruppe GmbH | ||
Full Title: A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus stand... | ||
Medical condition: HR+/HER2- early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005407-38 | Sponsor Protocol Number: MK-3475-B49 | Start Date*: 2021-08-17 | |||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positi... | |||||||||||||||||||||||
Medical condition: Treatment of patients with HR+/HER2- locally recurrent inoperable or MBC whose tumors express PD-L1 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) IT (Ongoing) GR (Trial now transitioned) HU (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022902-41 | Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g | Start Date*: 2011-09-26 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa... | |||||||||||||
Medical condition: Patients with operable HER2-positive primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) CZ (Completed) ES (Ongoing) FR (Ongoing) IE (Ongoing) SE (Ongoing) DK (Completed) SI (Ongoing) NL (Ongoing) BE (Ongoing) SK (Completed) AT (Trial now transitioned) IT (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.